Avid Bioservices, Inc.
Avid Bioservices is a dedicated biologics contract development and manufacturing organization (CDMO) with over 30 years of experience in biologics development, manufacturing, and regulatory compliance. They focus on transforming the CDMO experience with expertise, world-class facilities, and personalized processes to help bring high-quality, lifesaving drugs to market. Recently, they have been acquired by GHO Capital Partners and Ampersand Capital Partners, and they operate state-of-the-art facilities including a mammalian protein CGMP Drug Substance Line 3. The company actively participates in industry conferences and events such as BPI West, ASC BioT, BIO 2025, and others, showcasing their commitment to innovation and industry leadership.
Industries
Nr. of Employees
large (251-1000)
Avid Bioservices, Inc.
Products
Mammalian Protein Development & Manufacturing Services
Provides end-to-end solutions for biologics development from early stages to commercial-scale production.
Viral Vector Development & Manufacturing Services
Specializes in the design, optimization, and scalable production of viral vectors for gene therapy and vaccine applications.
Mammalian Protein Drug Substance Development & Manufacturing
Offers development, transfer-in, optimization, and scale-up of processes suitable for CGMP manufacturing.
Mammalian Protein Process Development
Supports research and development needs, process and analytical development, technical transfer, and optimization.
Mammalian Protein CGMP Manufacturing
Provides manufacturing from early-stage development to large-scale commercialization.
Mammalian Protein Analytical Services
Offers experience in transferring, developing, qualifying, and validating client assays.
Mammalian Protein Development & Manufacturing Services
Provides end-to-end solutions for biologics development from early stages to commercial-scale production.
Viral Vector Development & Manufacturing Services
Specializes in the design, optimization, and scalable production of viral vectors for gene therapy and vaccine applications.
Mammalian Protein Drug Substance Development & Manufacturing
Offers development, transfer-in, optimization, and scale-up of processes suitable for CGMP manufacturing.
Mammalian Protein Process Development
Supports research and development needs, process and analytical development, technical transfer, and optimization.
Mammalian Protein CGMP Manufacturing
Provides manufacturing from early-stage development to large-scale commercialization.
Mammalian Protein Analytical Services
Offers experience in transferring, developing, qualifying, and validating client assays.
Services
Clinical and commercial GMP manufacturing of therapeutic proteins and antibodies with large-scale single-use bioreactor capacity and GMP lot release.
Integrated upstream and downstream development including cell culture optimization, purification development, DoE-based characterization, and pilot production for preclinical material.
Analytical assay development, method transfer, qualification and validation, biophysical characterization, impurity testing, stability programs, and GMP lot release testing.
Quality systems and regulatory support to maintain compliance with global regulators, readiness for inspections, and support for multi-market approvals.
In-person representation at industry conferences and trade shows to support business development, partner introductions, and stakeholder outreach within the biopharma ecosystem.
Clinical and commercial GMP manufacturing of therapeutic proteins and antibodies with large-scale single-use bioreactor capacity and GMP lot release.
Integrated upstream and downstream development including cell culture optimization, purification development, DoE-based characterization, and pilot production for preclinical material.
Analytical assay development, method transfer, qualification and validation, biophysical characterization, impurity testing, stability programs, and GMP lot release testing.
Quality systems and regulatory support to maintain compliance with global regulators, readiness for inspections, and support for multi-market approvals.
In-person representation at industry conferences and trade shows to support business development, partner introductions, and stakeholder outreach within the biopharma ecosystem.
Expertise Areas
- Clinical and commercial biologics manufacturing
- Upstream and downstream process development
- Analytical method development and QC testing
- Regulatory compliance and inspection readiness
Key Technologies
- Single-use bioreactor systems
- Fed-batch and perfusion cell culture
- Tangential flow filtration (TFF) / UF-DF
- Chromatography (affinity, ion exchange, HIC, SEC)
News & Updates
GHO Capital Partners and Ampersand Capital Partners have completed the acquisition of Avid Bioservices, positioning the company for significant growth.
Avid Bioservices has issued a notice regarding fundamental changes to its convertible notes following a merger.
Shareholders of Avid Bioservices have approved the transaction with GHO Capital Partners and Ampersand Capital Partners.
The acquisition of Avid Bioservices by GHO Capital Partners and Ampersand Capital Partners in a $1.1 billion deal has been completed.
Avid Bioservices announced participation in the Craig-Hallum Bioprocessing Conference.
GHO Capital Partners and Ampersand Capital Partners have completed the acquisition of Avid Bioservices, positioning the company for significant growth.
Avid Bioservices has issued a notice regarding fundamental changes to its convertible notes following a merger.
Shareholders of Avid Bioservices have approved the transaction with GHO Capital Partners and Ampersand Capital Partners.
The acquisition of Avid Bioservices by GHO Capital Partners and Ampersand Capital Partners in a $1.1 billion deal has been completed.
Avid Bioservices announced participation in the Craig-Hallum Bioprocessing Conference.